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homogenates and bovine serum albumin indicate that the 
drugs are not converted enzymatically to DNA-reactive 
intermediates. Furthermore, results with buccal- and lung-
derived human cells show that gaseous treatment of the 
cells under conditions which reflect the exposure situation 
in drug users may cause damage of the genetic material in 
epithelia of the respiratory tract. Since DNA instability is 
involved in the etiology of cancer, these findings can be 
taken as an indication that consumption of the SCs may 
cause tumors in the respiratory tract of consumers.
Keywords Synthetic cannabinoids · Genotoxicity · 
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Abstract Aim of this study was the investigation of the 
genotoxic properties of XLR-11 [1-(5-fluoropentyl)-1H-in-
dol-3-yl](2,2,3,3-tetramethylcyclopropyl)methanone, a 
widely consumed synthetic cannabinoid (SC), and of the 
benzoyl indole RCS-4 (4-methoxyphenyl)(1-pentyl-1H-in-
dol-3-yl)methanone). We characterized the DNA-damaging 
properties of these drugs in different experimental systems. 
No evidence for induction of gene mutations was detected 
in bacterial (Salmonella/microsome) tests, but clear dose-
dependent effects were found in in vitro single cell gel 
electrophoresis (SCGE) assays with human lymphocytes 
and with buccal- and lung-derived human cell lines (TR-
146 and A-549). These experiments are based on the deter-
mination of DNA migration in an electric field and enable 
the detection of single- and double-strand breaks and apu-
rinic sites. Furthermore, we found that both drugs induce 
micronuclei which are formed as a consequence of chro-
mosomal aberrations. The lack of effects in SCGE experi-
ments with lesion-specific enzymes (FPG, Endo III) shows 
that the DNA damage is not caused by formation of oxi-
datively damaged bases; experiments with liver enzyme 
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Introduction
Synthetic cannabinoids (SCs) are drugs which bind to the 
cannabinoid receptors CB1 and CB2. They cause simi-
lar psychotropic effects as Δ9-tetrahydrocannabinol (Δ9-
THC). These compounds are marketed worldwide in form 
of herbal mixtures (“legal highs”) as a surrogate for mari-
juana (Spaderna et al. 2013).
The toxic properties of these drugs are in general 
only poorly investigated. We found in a recent investiga-
tion with human-derived cells that some of them cause 
damage of the genetic material, while other toxic 
effects (acute cytotoxicity, immunological effects and 
estrogenic properties) were only moderate or lacking 
(Koller et al. 2013, 2014). Genetic damage is involved in 
etiology of various diseases, i.e., it plays a key role in the 
induction of cancer and is also involved in neurodegen-
erative disorders, atherosclerosis, infertility and aging 
(Ames and Gold 1997; Ames et al. 1993). Therefore, 
our previous findings indicate that adverse effects, which 
are related to DNA damage, may be induced in users of 
these drugs.
Aim of the present study was the characterization of the 
genotoxic properties of XLR-11, a tetramethylcyclopropyl 
indole drug. This compound was one of the most widely 
used SCs in the USA and in the Europe and replaced 
several other drugs such as JWH-018 and AM-2201 
(Uchiyama et al. 2013). It was named after the first fuel 
rocket developed in the USA and binds to both cannabinoid 
receptors (Wiley et al. 2013). Furthermore, we included in 
the present investigation also experiments with RCS-4, an 
indole-based SC which contains a benzoyl ring. It is struc-
turally related to other drugs such as AM-694 and RCS-8 
(Logan et al. 2012) and less frequently consumed than 
XLR-11 (Seely et al. 2013). Figure 1a, b depicts the chemi-
cal structures of the two compounds.
We used different experimental models to characterize 
the genotoxic properties of these drugs including bacterial 
mutagenicity tests with Salmonella typhimurium strains 
which detect gene mutations (Maron and Ames 1983) 
and single cell gel electrophoresis (SCGE or “comet”) 
assays which are based on the measurement of migration 
of DNA in an electric field and detect single- and double-
strand DNA breaks and apurinic sites (Tice et al. 2000). 
These experiments were conducted with the buccal-derived 
human cell line TR146 (Rupniak et al. 1985) and addition-
ally with peripheral human lymphocytes. To determine 
whether the drugs are converted by phase I enzymes to 
DNA-reactive intermediates, further SCGE experiments 
were conducted with liver enzyme homogenate and bovine 
serum albumin. The formation of oxidatively damaged 
DNA was assessed in comet experiments by use of lesion-
specific enzymes (formamidopyrimidine DNA glycosylase 
and endonuclease III).
Since “comets” disappear as a consequence of repair 
processes, it is not clear whether they cause persisting 
alterations of the genetic material. To clarify this ques-
tion, we studied in subsequent experiments the induction of 
micronuclei (MNi) which are formed as a consequence of 
structural and numerical chromosomal aberrations and of 
other nuclear anomalies in cytome assays (Fenech 2007).
Finally, experiments were conducted with an Air–liquid 
interface exposure system which allows investigation of the 
genotoxic and acute toxic effects of the drugs under real-
istic exposure conditions. It mimics the physiological con-
ditions in the respiratory tract and eliminates the interac-
tions of potential constituents with culture media (Thorne 
and Adamson 2013). These experiments were conducted 
with the buccal cells (TR-146) and with the human cell line 
A-459 which is derived from lung fibroblasts (Lieber et al. 
1976) and was used in earlier gaseous exposure experi-
ments (Majeed et al. 2014; Tang et al. 2012).
Fig. 1  Chemical structures of 
the test compounds. a RCS-4 
(4-methoxyphenyl)(1-pentyl-
1H-indol-3-yl)methanone, CAS 









Low-melting-point agarose (LMPA) and normal-melting-
point agarose (NMPA) were obtained from Gibco (Paisley, 
UK). Inorganic salts, 2-aminoanthracene (2-AA), dimethyl 
sulfoxide (DMSO), propidium iodide, hydrogen peroxide, 
RPMI 1640, Triton X-100, Trizma base, trypan blue, Histo-
paque 1077, fetal calf serum (FCS), bovine serum albumin 
(BSA), 2-nitrofluorene (2-NF), 4-nitroquinoline-N-oxide 
(4-NQO), mitomycin C, cytochalasin-B, Dulbecco’s phos-
phate-buffered saline (DPBS), Dulbecco’s modified Eagle’s 
medium (DMEM), l-glutamine and sodium pyruvate were 
purchased from Sigma-Aldrich (Steinheim, Germany). 
Phytohemagglutinin (PHA) was ordered from Remel Inc., 
(Lenexa, USA). Aroclor™ 1254-induced rat liver S9 was 
purchased from Trinova Biochem GmbH (Giessen, Ger-
many). Trypsin–EDTA was obtained from Life Technolo-
gies (Karlsruhe, Germany).
Test compounds
The synthetic cannabinoids (4-methoxyphenyl)(1-pentyl-
1H-indol-3-yl)methanone, (RCS-4, CAS 1345966-78-
0; C21H23NO2) and [1-(5-fluoropentyl)-1H-indol-3-yl]
(2,2,3,3-tetramethyl-cyclopropyl)methanone (XLR-11, 
CAS 1364933-54-9; C21H28FNO) were provided as crystal-
line solids (purity ≥98 %) by the State Bureau of Criminal 
investigation Baden-Württemberg and the Finnish customs, 
respectively. Stock solutions were prepared in DMSO and 
stored at −20 °C.
Salmonella/microsome assays
The compounds were tested in Ames microplate format 
(MPF) assays according to the instructions of the manu-
facturer [Ames MPF™, Xenometrix AG, Allschwil, Swit-
zerland; see also Fluckiger-Isler and Kamber (2012)]. This 
procedure differs from the plate incorporation protocol as it 
is performed in liquid medium with 384-well microplates 
and it was used as lower amounts of the test compounds 
that are required than in plate incorporation experiments. 
The experiments were conducted with the S. typhimurium 
strains TA98 (hisD3052, rfa, Δbio, uvrB, pKM101) and 
TA100 (hisG46, rfa, Δbio, uvrB, pKM101). TA100 detects 
base pair substitutions while TA98 is sensitive towards 
mutagens which cause frameshifts (Maron and Ames 
1983).
Different concentrations of the drugs (0.01, 0.1 and 
1.0 mM) were tested in the presence and absence of met-
abolic activation mix (S9). 4-Nitroquinoline-N-oxide 
(4-NQO, 0.1 µg/mL) and 2-nitrofluorene (2-NF, 0.4 µg/
mL) were used as positive controls in assays without 
metabolic activation. 2-Aminoanthracene (2-AA, 5.0 µg/
mL) was used as positive control in all experiments with 
S-9 mix. Stock solutions of the test compounds were pre-
pared with DMSO which was also added to control cultures 
according to the instructions of the manufacturer (Ames 
MPF™, Xenometrix AG, Allschwil, Switzerland).
Mutagenic effects were determined by measuring 
changes of the color of the wells from purple to yellow. 
The number of wells which contained his+ revertants was 
counted and compared with the solvent control. Each dose 
was tested in triplicate.
Collection of lymphocytes
Peripheral blood samples were collected from three 
healthy, non-smoking male volunteers without any history 
of recent disease or exposure to toxic chemical agents. The 
samples were collected by venipuncture in heparinized 
tubes (BD, Heidelberg, Germany). Blood samples were 
collected for comet and MN assays on separate days from 
the same individuals.
For comet assays, blood samples from three donors 
were centrifuged (650g, 10 min, 4 °C) immediately 
after collection. Subsequently, the plasma was removed, 
the cell suspensions were diluted with RPMI 1640, and 
the lymphocytes were isolated by gradient centrifuga-
tion (800g, 16 °C min, 16 °C) with Histopaque 1077 in 
Accuspin tubes (Sigma-Aldrich, Steinheim, Germany). 
The cells were collected and washed twice in RPMI 1640 
(332g, 10 min 16 °C), suspended in freezing medium 
(Biofreeze, Biochrom AG, Berlin, Germany) and stored 
at −80 °C.
Blood samples for cytokinesis-block micronucleus 
(CBMN) assays were collected from the same volunteers. 
The isolation of lymphocytes was performed as described 
by Fenech (2007). The cells were cultivated under stand-
ard conditions (37 °C, humidified atmosphere, 5 % CO2) in 
RPMI 1640 medium supplemented with 10 % FCS.
Cultivation of human cell lines (TR‑146 and A‑549)
The human cell line TR-146 is derived from buccal epithe-
lial tissue (Rupniak et al. 1985). The cells were obtained 
from J.G. Rheinwald (Dermatology Institute of Boston, 
MA USA). They were cultured under standard conditions 
(37 °C, humidified atmosphere, 5 % CO2) in DMEM which 
was supplemented with 10 % FCS. The cell line was stored 
in liquid nitrogen and was used for the experiments after 
recultivation at the fourth to the sixth passage from the 
stock cultures. The media were changed every 2–3 days; 
when the cultures had reached confluence, the cells were 
washed with Dulbecco’s phosphate-buffered saline (DPBS, 
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Sigma-Aldrich, Steinheim, Germany), detached with 
Trypsin/EDTA, centrifuged and sub-cultured.
The human lung fibroblast line A-549 was obtained from 
the American Type Culture Collection (ATCC, Manassas, 
USA). The cells were used as an in vitro model for type 
II pulmonary epithelial cells and cultivated in RPMI 1640 
medium (low glucose, with l-glutamine), supplemented 
with 10 % FCS and U/mL penicillin/streptomycin (Invit-
rogen, Darmstadt, Germany) under humidified conditions 
(5 % CO2; humidified atmosphere, 37 °C). Frozen human 
lung fibroblast cells were thawed and used for the experi-
ments after the fourth to the sixth passage. Every 2–3 days, 
the medium was changed. At 85–90 % confluence, the cells 
were washed with Dulbecco’s PBS (Ca–Mg-free), then 
harvested using 0.25 % trypsin–EDTA and sub-cultured in 
T-25 cm2 flasks (Greiner Bio-One, Austria) or seeded on 
inserts.
Single cell gel electrophoresis (SCGE) assays 
under standard conditions
SCGE assays were conducted under standard alkaline con-
ditions (Tice et al. 2000). Frozen lymphocytes were thawed 
in a water bath (37 °C) and centrifuged (200 g, 5 min at 
16 °C). Subsequently, the pellets were dissolved in RPMI 
1640 and washed twice.
Aliquots of lymphocyte suspensions or of TR-146 cells 
(1 × 105 cells) were treated (lymphocytes for 3 h, TR-146 
for 24 h) with different concentrations (50–150 µM) of 
the synthetic cannabinoids. H2O2 (50 µM) was used as a 
positive control. Solutions of the drugs were prepared from 
deep-frozen stocks before each experiment and further dis-
solved in serum-free medium. After incubation in the dark 
(37 °C), shaking (250 rpm), the cells were washed twice 
with RPMI 1640 (containing 10 % FCS) and centrifuged 
(200g, 8 min, 16 °C). After centrifugation, the cytotoxic 
activities of the drugs were determined with the trypan blue 
exclusion test (Lindl and Bauer 1994); then the pellets were 
re-suspended in low-melting-point agarose (0.5 % LMPA). 
Subsequently, the cells were spread on pre-coated agarose 
slides (1.5 % NMPA) and lysed in the dark at 4 °C for at 
least 60 min. After 30 min unwinding under alkaline condi-
tions (pH >13), electrophoresis was carried out for 30 min 
(300 mA, 1.0 V/cm, at 4 °C) and neutralization was per-
formed twice for 8 min. Air-dried slides were stained with 
propidium iodide (10 µg/mL); subsequently the percentage 
of DNA in the tails was measured by use of a computer-
aided image analysis system (Comet IV, Perceptive Instru-
ments Ltd., Burry St. Edmunds´, UK). For each experimen-
tal point, three slides were prepared from each donor and 
50 nuclei were evaluated randomly from each slide.
In addition to the dose–response experiments, assays 
were performed in which we investigated the impact of 
rat liver enzyme homogenate (S9) and bovine serum albu-
min (BSA) on comet formation. The incubation mixtures 
contained the indicator cells (1 × 105 cells), solutions of 
the two drugs (final concentration 150 µM) and either PBS 
or fresh S-9 mix (final protein concentration 30 mg/mL) 
which was prepared according to the standard recipe of 
Maron and Ames (1983) or BSA solution (30 mg protein/
mL). The mixtures were incubated for 3 h (37 °C; shak-
ing 250 rpm); subsequently the cells were washed and pro-
cessed as described above.
Single cell gel electrophoresis (SCGE) assays 
with lesion‑specific enzymes
To assess the impact of the drugs on formation of oxida-
tively damaged purines and pyrimidines, additional experi-
ments with lesion-specific enzymes (formamidopyrimidine 
DNA glycosylase, FPG and endonuclease III, Endo III) 
were conducted according to the protocol of Collins and 
Dušinská (2002). The cells (TR-146) were exposed to the 
test compounds as described above. To establish the opti-
mal amounts of the enzymes, calibration experiments were 
carried out according to the protocol of Collins et al. (1997) 
before the main experiments (results not shown).
After lysis, the slides were washed twice with enzyme 
reaction buffer (pH 8.0) for 8 min. Subsequently, the 
nuclei were treated either with 50 µL of the enzyme solu-
tions or with the enzyme buffers. The incubation time for 
FPG was 30 min and for Endo III 45 min at 37 °C, respec-
tively. After the treatment, electrophoresis was carried out 
under standard conditions (30 min, 300 mA, 1.0 V/cm, at 
4 °C, pH >13). After lysis and electrophoresis, the slides 
were processed and evaluated as described above. For each 
experimental point, two cultures were made. From each 
culture, two slides were prepared and 50 cells were evalu-
ated from each slide. The values which were obtained with 
the enzyme buffers were subtracted from the results which 
were obtained with the enzyme solutions.
Cytokinesis‑block micronucleus (CBMN) assays 
with human lymphocytes and TR‑146 cells
Lymphocyte cultures were set up according to the recom-
mendations of Fenech (2007) in agreement with the OECD 
guideline 487 (OECD 2010). Since human lymphocytes 
are more sensitive toward genotoxins during S, G2 and 
M phase than freshly collected cells which are in the G0 
phase, mitogenic stimulation was performed with PHA 
before treatment of the cells with the test compounds.
Briefly, 1 × 106 lymphocytes were added to 750 µL culture 
medium (RPMI 1640 containing 10 % FCS, 2.0 mM l-glu-
tamine and 1.0 mM sodium pyruvate) and 10 µL of a PHA 
solution (30 µg/mL) to stimulate cell division. For each 
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experimental point, two cultures were made; they were incu-
bated at 37 °C in humidified atmosphere with 5 % CO2 with 
PHA for 44 h. Subsequently, the medium was replaced by 
fresh medium without FCS which contained different concen-
trations of the drugs (25.0, 50.0, 75.0, 100.0 and 150.0 µM). 
Treatment was performed for 3 h (37 °C, shaking 250 rpm in 
the dark). Cytochalasin-B was added to the cultures at a final 
concentration of 4.5 µg/mL to block cytokinesis after treat-
ment with the drugs. Mitomycin C (1.0 µg/mL) was used as 
a positive control; serum-free medium with DMSO (1.0 %) 
was added to untreated cultures as a solvent control. After 
the treatment, the cells were washed twice with RPMI 1640 
(332g, 10 min., 16 °C) and the pellets re-suspended in cul-
ture medium. The cells were harvested after 72 h. Slides were 
made with the cyto-centrifugation method (Fenech 2007); 
after drying, they were fixed and stained with Diff Quick 
(Dade Behring, Deerfield, IL, USA).
The protocol for experiments with TR-146 is described 
in detail in the paper of Koller et al. (2014). Briefly, the 
cells were seeded in 6-well plates and allowed to attach 
overnight. Subsequently, the medium was removed, and the 
cells were washed with DPBS; then they were treated with 
different concentrations of the test compounds in serum-
free medium for 24 h. Mitomycin C (1.0 µg/mL) was used 
as a positive control; medium with DMSO (1 %) was used 
in the control cultures. After exposure of the cells to the 
drugs and washing with PBS, they were incubated with 
cytochalasin-B (3.0 µg/mL) and DMEM (with 10 % FCS) 
for another 24 h. Subsequently, the cells were washed, 
trypsinized and processed as described above.
From each culture, 2000 cells were evaluated. Different 
endpoints were scored, namely mono-nucleated, binucleated 
(BN) and multi-nucleated cells as well as the rates of binu-
cleated cells with MN (BN–MN), the total number MN in 
binucleated cells (MNi), nuclear buds (Nbuds) and nucleo-
plasmatic bridges (NPBs). The cytokinesis-block prolifera-
tion indices (CBPI) were calculated with 500 cells according 
to the formula CBPI = [M1 + 2M2 +3(M3 + M4)]/N (N 
is the total number of scored cells, M1 − M4 refers to the 
number of cells with one to four nuclei). The toxicity of the 
compounds was indirectly assessed by the assumption that a 
CBPI of 1.0 corresponds to 100 % cytotoxicity. Five concen-
trations of each drug were used to determine the CBPI values. 
In agreement with OECD guideline 487 (OECD 2010), only 
doses were analyzed in regard to formation of MN and other 
nuclear anomalies which caused less than 60 % cytotoxicity.
Determination of acute toxic and genotoxic properties 
of the drugs by use of air–liquid interface exposure 
system
The experiments were conducted with the VITROCELL® 
cultivation and exposure system (12 HT/HT CF modules 
Waldkirch, Germany) with 6 cell culture inserts which is 
based on the cultivation of cells on porous membrane (Majeed 
et al. 2014). The system has separate exposure modules, each 
positioning three inserts which were used for parallel expo-
sures to controls and test compounds. The aerosol is humidi-
fied up to 80 % under controlled temperature. The cells are 
nourished with serum-free medium from the basal surface, 
while being exposed to the aerosolized test compound in air–
liquid interface (ALI) from the top that was flowing perpen-
dicular onto the surface with constant air flow (5 mL/min).
The experiments were performed as described in an arti-
cle of Weber et al. (2013) with slight modifications. The 
indicator cells (TR-146 and A-549, 1x105 cells per insert) 
were transferred and grown in special Transwell® inserts 
(ThinCerts™ Cell Culture Inserts, Greiner Bio-One, Fric-
kenhausen, Germany) for 24 h before each experiment. 
Before the exposure, the media were removed from the api-
cal surface of the cultures and transferred in sterile environ-
ment into the VITROCELL® exposure system.
The cannabinoids (5 and 20 mg of each drug) were 
vaporized by a commercial vaporizer (Vaporizer-BLK-
Titan, Near Dark GmbH, Hennef, Germany). Briefly, the 
drugs were placed inside the heating chamber of the appa-
ratus and the temperature set on 220 °C to vaporize the 
chemicals. The cells were exposed to the vaporized drugs 
for 10 min (flow rate 5 mL/min/well) on the air–liquid 
interfaces via trumpets raised 0.5 cm above the cell layers. 
Flow and vacuum rates within the system were set using 
mass flow meters (Analyt-MTC GmbH, Mülheim, Ger-
many). For each experimental point, two cultures were 
exposed from each culture and three slides were made. The 
experiments were conducted in duplicate.
After the treatment, the inserts were removed and trans-
ferred back to regular 12-well plates. Complete medium 
with 10 % FBS was added to both (the apical and the basal) 
surfaces. Subsequently, the cells were cultivated in an incu-
bator, and then, the cultures were trypsinized and the cells 
analyzed in SCGE assays as described above. The cyto-
toxic effects of the drugs were monitored in all experiments 
with the trypan blue exclusion test (Lindl and Bauer 1994).
Determination of concentrations of SCs in two cell lines
Quantification of the synthetic cannabinoids in cells was 
done using a LC/ESI–MS/MS system consisted of a QTrap® 
4000 mass spectrometer fitted with a TurbolonSpray interface 
(AB Sciex, Darmstadt, Germany), and a Shimadzu Promi-
nence HPLC system (Duisburg, Germany) was used. Chro-
matographic separation was achieved using the conditions 
of Huppertz et al. (2014) with a Kinetex® 2.6 u C18 100 Ǻ, 
100 × 2.1 mm column (Phenomenex Ltd., Aschaffenburg, 
Germany) with a matching guard column and gradient elution 
with a flow rate of 0.5 mL/min (Huppertz et al. 2014).
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The scheduled multiple reaction monitoring (sMRM) 
method contained two transitions for XLR-11, XLR-11 
Isomer and RCS-4 and one transition for the ISTD. The 
MRM transitions were only recorded in a time window 
of ±50s around the expected retention time. For all com-
pounds, the declustering potential (DP), the entrance poten-
tial (EP), the collision energy (CE) as well as the cell exit 
potential (CXP) were optimized. The mass spectrometer 
was operated in positive ionization mode. The method used 
was fully validated according to the guidelines of GTFCh; 
LODs are 0.04 ng/mL for RCS-4 and 0.03 ng/mL for XLR-
11 and its isomer. Quantification was done using a 5-point 
calibration in the range of 0.1–1.25 ng/mL. After exposure 
of the cells (1 × 105/insert) grown on the inserts, they were 
sonicated with 1000 µL MeOH, and subsequently, concen-
trations of the drugs were determined.
Statistical analyses
All results were analyzed with GraphPad Prism 5 software 
system (LaJolla, CA, US). The data from the bacterial tests, 
from the SCGE experiments and from the MN assays are 
presented as mean ± SD.
The results of CBMN assays were analyzed with the 
Kruskal–Wallis test followed by Dunn’s test. The findings 
of SCGE assays (under standard conditions and after treat-
ment with lesion-specific enzymes) were analyzed by one-
way ANOVA followed by Dunnett’s multiple-comparisons 
test. The Student’s t test was used to analyze the data after 
liquid exposure to the drugs. Differences were considered 
as significant, when the p values were ≤0.05.
Results from Ames MPF assays were evaluated 
according to Fluckiger-Isler and Kamber (2012). Briefly, 
the mean numbers of positive (yellow) wells per dose were 
calculated from triplicates, and the fold increase above the 
baseline values was determined for each dose (for further 
details, see Fluckiger-Isler and Kamber 2012). A ≥2-fold 
increase compared to the baseline (control) value was con-
sidered as a positive result.
Results
Salmonella/microsome assays
The results of representative bacterial mutagenicity tests 
are summarized in Table 1. It can be seen that negative 
results were obtained with both drugs under all experimen-
tal conditions, while clear effects were found with the posi-
tive controls.
Single cell gel electrophoresis experiments (standard 
conditions)
Figure 2 depicts the results which were obtained with the 
drugs in the SCGE experiments with lymphocytes (Fig. 2a, 
b) and with TR-146 cells (Fig. 2c, d). With both SCs, dose-
dependent induction of DNA migration was found in both 
cell lines. The doses which were required to cause signifi-
cant effects were in most experimental series ≥100 µM; 
with RSC-4, a clear effect was seen in the buccal-derived 
cells already with 50 µM. The positive control (H2O2, 
50 µM) induced in all experiments significant induction of 
DNA migration.
The cytotoxic effects of the drugs were monitored with the 
trypan blue exclusion test (Lindl and Bauer 1994). The ratio of 
Table 1  Results of gene 
mutation assays obtained with 
the bacterial indicator strain, 
Salmonella typhimurium TA98 
and TA100 in the presence and 
absence of metabolic activation 
mix
The Salmonella typhimurium strains TA100 and TA98 were exposed to different concentrations of the 
SCs in the presence and absence of metabolic activation mix (rat liver S9) as described in materials and 
methods. The results were considered positive when the response was a ≥2-fold increase over that of the 
baseline. Numbers indicate means ± SDs of results obtained in three parallel experiments; asterisks indi-
cate values which are significantly different from those found in the respective controls
* Significant differences from the controls cultures (p < 0.05)
a Positive controls without S9: 4-NQO (0.1 µg/mL) and 2-NF (0.4 µg/mL); with S9: 2-AA (5.0 µg/mL); 
DMSO was added to the negative controls
Compounds Concentration TA98 − S9 TA98 + S9 TA100 − S9 TA100 + S9
mM Mean ± SD Mean ± SD Mean ± SD Mean ± SD
Neg. Cont. 0.00 0.7 ± 0.6 1.3 ± 1.2 3.7 ± 0.6 3.7 ± 1.5
RCS-4 0.01 0.3 ± 0.6 0.7 ± 1.2 3.7 ± 1.2 4.0 ± 3.5
0.10 0.3 ± 0.6 3.0 ± 1.7 4.7 ± 0.6 4.0 ± 2.6
1.00 1.0 ± 1.7 1.7 ± 0.6 2.7 ± 0.6 7.6 ± 1.2
XLR-11 0.01 0.3 ± 0.6 2.3 ± 1.5 5.3 ± 2.3 6.3 ± 2.9
0.10 0.3 ± 0.6 1.7 ± 1.2 5.0 ± 2.1 6.7 ± 1.2
1.00 1.0 ± 1.0 0.7 ± 1.2 3.3 ± 1.5 6.0 ± 2.0
Pos. Cont.a 38.3 ± 1.2* 48.0 ± 0.0* 48.0 ± 0.0* 36.0 ± 1.0*
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“blue” cells (with membrane damage) was in all experiments 
<20 %; it is known that higher values may cause misleading 
results in SCGE experiments (Henderson et al. 1998).
SCGE experiments with lesion‑specific enzymes
Several investigations indicate that SCs cause inflamma-
tions which may lead to release of reactive oxygen spe-
cies [for further details, see (Bileck et al. 2015; Jean-Gilles 
et al. 2015)]. Therefore, we used a modified protocol of 
the SCGE technique to monitor formation of oxidatively 
damaged purines and pyrimidines. The results of these 
experiments are summarized in Fig. 3a–c. It can be seen 
that no evidence for increased formation of oxidized DNA 
bases was detected in the present experiments.
SCGE experiments with liver S9 mix and bovine serum 
albumin
To find out whether addition of phase I enzymes which 
are represented in liver-derived homogenate (S9) leads to 
activation of the drugs, further experiments were carried 
out. The results are depicted in Fig. 4a, b. It can be seen 
that the extent of comet formation caused by both drugs 
was reduced in the presence of the activation mix by 16 
and 18 %, respectively. A similar effect was seen when the 
enzyme mix was replaced by BSA solution (which con-
tained an identical amount of protein as the activation mix).
Induction of acute toxic and genotoxic effects 
after vaporized exposure
The results of experiments in which the indicator cells were 
exposed in an air–liquid interface system are summarized 
in Table 2. Both SCs caused significant induction of DNA 
migration in the two indicator cell lines. Cytotoxic effects 
were in all experimental series below 20 % (columns 3 and 
4). RCS-4 was in both indicator cell lines a more potent 
genotoxin, i.e., the extent of comet formation (expressed as 
% DNA in the tail) was under identical conditions approxi-





































































































Fig. 2  Impact of treatment of lymphocytes (a, b) and of human-
derived buccal cells (TR-146; c, d) with RCS-4 and XLR-11 on 
comet formation. Lymphocytes were treated for 3 h, TR-146 cells for 
24 h. Bars indicate mean ± SD of results obtained with three par-
allel cultures per experimental point in a representative experiment 
(from each culture, 2 slides were made and 50 cells were evaluated 
per slide). Stars indicate statistical significance (p ≤ 0.05, ANOVA)
























































































Fig. 3  Impact of treatment of human-derived buccal cells (line 
TR-146) with synthetic cannabinoids on formation of oxidatively 
damaged purines (FPG-sensitive sites, a, b) and pyrimidines (Endo 
III sensitive sites, c, d). The cells were exposed to the drugs for 24 h. 
Subsequently, the nuclei were isolated and treated with enzymes or 
with the buffers only as described in the “Materials and methods” 
section. Subsequently, DNA migration was monitored. Bars indicate 
means ± SDs of results obtained with two cultures per experimen-
tal point in a representative experiment (values which were obtained 
with the enzyme buffers were subtracted from values which were 
obtained with the enzymes). From each culture, two slides were made 
and 50 cells were evaluated per slide
A BRCS-4





































Fig. 4  a, b Impact of rat liver S9 and bovine serum albumin (BSA) 
on SC-induced DNA migration in human lymphocytes. The cells 
were treated with solutions of the drugs (150 µM RCS-4 or XLR-
11) with and without S9 mix or BSA (final protein concentration 
0.3 mg/mL). After treatment of the cells, DNA migration was deter-
mined in SCGE experiments under standard condition. Bars represent 
means ± SDs of results obtained with tree cultures in parallel. From 
each culture, two slides were made and 50 cells were analyzed for 
comet formation per slide
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Impact of drugs on the induction of micronuclei 
and other nuclear anomalies
To find out whether treatment of human cells leads to for-
mation of MN, which reflect structural and numerical chro-
mosomal aberrations, cytome experiments were conducted. 
The results with lymphocytes and with TR-146 cells are 
summarized in Table 3.
Both compounds caused in both cell types induction of 
MNi. A clear effect was found in the lymphocytes with XLR-
11 with concentrations ≥100 µM, while in buccal-derived 
cells significant effects were detected already with a lower 
concentration (75 µM). Also RCS-4 caused a positive result 
in both types of indicator cells. A clear increase in the MN 
rates was detected in the lymphocytes with 50 µM; higher 
doses could be not evaluated due to inhibition of cell division.
With XLR-11 additionally a significant increase in other 
nuclear anomalies (Nbuds and NPBs) was observed in 
the blood cells and also in the buccal cells at high doses 
(100 and 150 µM, respectively). The rates of these anoma-
lies were also elevated in both cell types as a consequence 
of treatment with RCS-4, but these effects were only 
moderate and did not reach significance.
Discussion
Three different genotoxicity systems were used in the pre-
sent study to investigate the genotoxic properties of XLR-11, 
one of the most widely consumed SCs and, of the benzoyl 
indole RCS-4. Furthermore, attempts were made to character-
ize the molecular mechanisms which lead to damage of the 
genetic material and to find out whether adverse effects can 
be expected in drug users under realistic exposure conditions.
The negative results which were obtained in the Sal-
monella/microsome assays indicate that the drugs do not 
induce gene mutations. These findings were not unex-
pected; also with other indole SCs including UR-144, 
which is structurally related to XLR-11 (XLR-11 is the 
fluorinated form of UR-144) (Mohr et al. 2014), consist-
ently negative results were obtained in earlier bacterial 
mutagenicity tests (Koller et al. 2015); also the natural 
cannabinoid Δ9-THC does not cause induction of his+ 
revertants in Salmonella tester strains (NTP 1996). SCs 
with benzoyl structure like RCS-4 have not been studied 
before in microbial mutagenicity assays according to our 
knowledge, and the present findings show that the compound 
is devoid of activity under all experimental conditions.
On the contrary, clear evidence for induction of DNA 
damage was found in SCGE experiments which reflect 
single- and double-strand breaks as well as apurinic sites 
(Tice et al. 2000) in human lymphocytes and also in the 
buccal-derived cells (Fig. 2). In this context, it is notable 
that we observed induction of comet formation by other 
SCs in earlier experiments; for example, the cyclohexyl-
phenol CP-47,497-C8 caused significant induction of DNA 
migration in lymphocytes and in TR-146 cells (Bileck 
et al. 2015; Koller et al. 2014). Also with UR-144 and 
Table 2  Impact of vaporized 
exposure on the DNA stability 
in human-derived lung 
fibroblasts (A-549) and buccal 
(TR-146) cells
Numbers indicate means ± SDs of data obtained with three parallel cultures per experimental point in a 
representative experiment. From each culture, 3 slides were made and 50 cells were evaluated per slide
* Significant differences from the corresponding control (unexposed) cultures (Student’s t test, p ≤ 0.05). 
In each experiment, positive controls were included; i.e., cells were exposed for 5 min on ice H2O2 
(50 µM); in all these experiments, significant induction of DNA migration was observed (data not shown)
a Values indicate means of four measurements. 104 cells per insert were sonicated with 1000 µL MeOH; 
subsequently, the concentrations of the drug were determined (see “Materials and methods” section)
b n.d. not determined
c Cytotoxicity was evaluated by use of trypan blue exclusion method. Numbers (%) indicate the ratio of 
cells with clear cytoplasm (cells without membrane damage) to total number of evaluated cells
Compounds Dose (mg) HPLC analyses 
(ng/mL)a
Cytotoxic activity  
(% cells of control)c
DNA migration  
(% DNA in tail)
A-549 TR-146 A-549 TR-146 A-549 TR-146
RCS-4 0.0 0.0 0.0 96.17 ± 5.46 97.87 ± 2.12 2.22 ± 0.75 2.03 ± 0.54
5.0 n.d.b 1358.0 86.33 ± 3.81 84.93 ± 2.87 8.10 ± 2.91* 6.98 ± 4.21*
0.0 0.0 0.0 94.67 ± 4.93 83.33 ± 1.53 3.72 ± 0.78 3.55 ± 1.09
20.0 n.d.b 2987.0 81.50 ± 2.27 82.80 ± 2.52 10.1 ± 3.20* 7.04 ± 1.89*
XLR-11 0.0 0.0 0.0 95.50 ± 3.42 97.87 ± 2.12 1.76 ± 0.71 1.63 ± 0.47
5.0 2010.0 1847.0 89.33 ± 9.35 87.60 ± 2.30 3.79 ± 1.07* 4.94 ± 2.03*
0.0 0.0 0.0 95.60 ± 3.53 91.00 ± 6.25 2.60 ± 1.01 2.44 ± 0.90
20.0 3030.0 4390.0 81.83 ± 3.54 84.47 ± 4.15 5.71 ± 1.42* 4.68 ± 1.24*
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alkylindazoles (AM-2201-IC and 5F-AKB-48), positive 
findings were obtained in human blood cells (Koller et al. 
2015) and representatives of naphthoylindoles (JWH-122 
and JWH-073) induced DNA migration in buccal-derived 
cells (Koller et al. 2013). The concentrations of the drugs 
which were required to cause significant effects were 
in most cases in the range between 50 and 100 µM; only 
with one compound (CP-47,497-C8), significant induction 
of DNA migration was seen at a substantially lower dose 
(10 µM). Also with Δ9-THC, induction of comets has been 
reported, for example, in the human-derived buccal cell 
line which was also used in the present experiments (Koller 
et al. 2013) and also in an environmental study with mus-
sels (Parolini and Binelli 2014).
It is not known in general whether positive results in 
SCGE experiments lead to persisting alterations of the genetic 
material. In order to find out whether the two drugs cause 
damage at the chromosomal level which is associated with 
adverse health effects, we conducted cytome assays in which 
we studied the formation of MNi which are a consequence 
Table 3  Impact of different synthetic cannabinoids on cytokinesis-block proliferation indices and on the rates of various nuclear aberrations in 
human mitogen-stimulated lymphocytes and in TR-146 cells
Human mitogen-stimulated lymphocytes from three individuals were treated with different concentrations of the test compounds for 3 h. TR-146 
cells were exposed to different concentrations of the drugs for 24 h. Numbers represent results (means ± SDs) obtained with duplicate cultures 
from four donors. Per experimental point, two slides were prepared and 1000 cells were evaluated from each slide
n.e. not evaluated due to inhibition of cell division
Please exchange C+  to Pos. Cont. mitomycin C (1.0 μg/ml)
CBPI cytokinesis-block proliferation indices, CT cytostasis (%); BN–MNi binucleated cells with micronuclei, MNi total number of micronuclei, 
Nbuds nuclear buds, NPBs nucleoplasmic bridges, 0 solvent control (DMSO), C+ mitomycin C (1.0 µg/mL)
* Significant differences from negative control (Kruskal–Wallis test followed by Dunns’s test, p ≤ 0.05)
a Number of binucleated cell with micronuclei
b Total number of MN
Compounds Concentration CBPI CT BN–MNia MNib Nbuds NPBs
µM Mean ± SD (%) Mean (‰) ± SD Mean (‰) ± SD Mean (‰) ± SD Mean (‰) ± SD
Peripheral human lymphocytes
RCS-4 0 2.02 ± 0.14 0.0 4.14 ± 0.52 4.25 ± 0.49 2.96 ± 1.55 1.67 ± 0.75
25 1.79 ± 0.15 22.6 6.45 ± 1.24 6.92 ± 0.96 3.73 ± 1.36 2.72 ± 1.24
50 1.52 ± 0.22* 49.0 8.01 ± 0.7* 8.46 ± 1.12* 3.51 ± 1.05 2.98 ± 1.37
75 1.25 ± 0.21* 75.5 n.e. n.e n.e. n.e.
100 1.19 ± 0.17* 81.4 n.e. n.e n.e. n.e.
150 1.07 ± 0.11* 80.4 n.e. n.e n.e. n.e.
XLR-11 25 1.86 ± 0.20 16.7 7.03 ± 1.76 7.26 ± 1.86 4.31 ± 1.95 1.81 ± 1.00
50 1.69 ± 0.22* 32.4 6.04 ± 2.50 6.16 ± 2.70 3.13 ± 0.77 2.45 ± 0.88
75 1.59 ± 0.14* 43.1 8.54 ± 1.02 8.78 ± 1.02 4.48 ± 1.02 2.77 ± 0.66
100 1.42 ± 0.13* 58.8 14.51 ± 4.40* 16.00 ± 5.71* 9.08 ± 3.04* 6.47 ± 3.02*
150 1.07 ± 0.05* 93.1 n.e. n.e. n.e. n.e.
Pos. Cont. 1 µg/mL 1.73 ± 0.16 48.36 ± 9.37* 50.62 ± 10.10* 12.44 ± 5.91* 2.68 ± 1.16
Buccal-derived human cells (TR-146)
RCS-4 0 2.35 ± 0.44 1.39 ± 0.40 3.44 ± 0.34 1.34 ± 0.14 1.32 ± 0.34
25 1.90 ± 0.75 33.3 3.46 ± 0.91 5.09 ± 1.09 3.92 ± 0.89 1.89 ± 0.97
50 1.86 ± 0.32 36.3 4.67 ± 1.04 6.02 ± 1.02 3.35 ± 0.76 1.79 ± 0.50
75 1.80 ± 0.25 40.7 6.89 ± 1.10* 7.99 ± 0.90* 3.92 ± 1.02 1.70 ± 0.40
100 1.35 ± 0.86* 74.1 n. e. n. e n. e. n. e
150 1.21 ± 0.45* 84.4 n. e. n. e n. e. n. e
XLR-11 25 1.99 ± 0.67 26.7 3.45 ± 0.97 5.20 ± 1.14 2.36 ± 0.89 1.12 ± 0.34
50 1.78 ± 0.14 42.2 4.49 ± 0.52 6.09 ± 1.00 2.42 ± 0.09 1.42 ± 0.88
75 1.75 ± 0.43* 44.4 6.46 ± 0.48* 7.08 ± 1.34* 2.99 ± 0.90 1.40 ± 0.36
100 1.51 ± 0.54* 62.2 8.98 ± 1.23* 10.08 ± 2.10* 2.32 ± 0.93 1.76 ± 0.78
150 1.20 ± 0.13* 85.2 n. e. n. e. n. e. n. e.
Pos. Cont. 1 µg/mL 1.68 ± 0.09 45.21 ± 5.20* 53.21 ± 7.60* 10.34 ± 3.20* 2.05 ± 1.06
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of structural and numerical aberrations (Norppa and Falck 
2003) as well as other nuclear anomalies. As described in 
the results sections (Table 2), positive results were obtained 
with both drugs in the buccal cell line (TR-146) and also in 
the lymphocytes. Also the rates of other nuclear anomalies 
namely Nbuds and NPBs lower elevated after treatment of the 
lymphocytes with XLR-11. It is known that these anomalies 
reflect genetic instability; i.e., NPBs are formed as a conse-
quence of dicentric chromosomes while Nbuds reflect gene 
amplification events (Fenech et al. 2011). The biological con-
sequences of the formation of these anomalies are not known 
at present; in the case of MNi, it is notable and it was shown 
by Bonassi and co-workers that increased rates of MN in 
peripheral lymphocytes of humans are associated with ele-
vated cancer risks (Bonassi et al. 2007, 2011).
The results of the present experiments allow to draw some 
conclusions in regard to the molecular mechanisms which 
lead to damage of the genetic material. The negative results in 
the bacterial assays indicate that the drugs do not form bulky 
DNA adducts as other groups of genotoxic carcinogens (e.g., 
aflatoxins, polycyclic aromatic hydrocarbons or heterocyclic 
amines) which cause gene mutations and lead to formation 
of his+ revertants. Furthermore, it can be also excluded that 
the induction of the comets which was observed in the SCGE 
experiments is causally related to formation of oxidatively 
damaged purines and pyrimidines. As shown in Fig. 3a–d, 
negative results were consistently obtained in experiments 
with lesion-specific enzymes (FPG, Endo III) which enable 
the detection of oxidized DNA bases (Collins 2014). In this 
context, it is notable that it was found in earlier investiga-
tions that the natural cannabinoid Δ9-THC induces oxidative 
damage in eukaryotic cells (Juknat et al. 2013; Parolini and 
Binelli 2014; Sarafian et al. 1999); furthermore, SCs were 
reported to cause induction of pro-inflammatory cytokines 
which may lead to release of reactive oxygen species (Bileck 
et al. 2015; Jean-Gilles et al. 2015).
Many genotoxic carcinogens require metabolic activa-
tion via phase I enzymes. To mimic these metabolic pro-
cesses which lead to formation of DNA-reactive metabo-
lites in vivo, liver enzyme homogenate (S9 mix) is added 
in routine mutagenicity assays (OECD 1997, 2010). As 
shown in Fig. 4a, b, we found that addition of the enzyme 
homogenate leads to a moderate (not significant) decrease 
in the genotoxic properties of both drugs. A similar effect 
was seen when BSA was added to the incubation mixtures. 
These findings show that enzymes which are contained 
in liver homogenates do not convert these drugs to DNA-
reactive intermediates. The observation of a reduction in 
their genotoxic activity which was seen with the enzyme 
mix and with pure proteins may be indicative of detoxifica-
tion via (non-enzymatic) protein binding. Similar, but more 
pronounced effects were seen in previous experiments with 
the SC, CP-47,497-C8 (Koller et al. 2014) and also with 
representatives of other groups of directly acting mutagens 
for example with isothiocyanates and alkylating agents 
(Kassie and Knasmuller 2000). It is possible that these 
detoxification reactions play also a role in the human body 
in addition to metabolic processes which are catalyzed by 
enzymes (e.g., hydroxylation, carboxylation and glucuro-
nidation) which were observed recently in in vitro experi-
ments with XLR-11 (Wohlfarth et al. 2013).
The last part of this study concerned the question whether 
the drugs cause DNA damage under realistic exposure condi-
tions. Only for few SCs (including RCS-4), data on their con-
centrations in body fluids of humans after consumption of the 
drugs are available (Kneisel et al. 2013; Teske et al. 2010). 
The concentrations which were detected are 2–3 orders of 
magnitude lower than those which caused positive results in 
the present experiments. In order to assess whether induction 
of genetic damage occurs in users as a consequence of inhala-
tion of the drugs, we conducted with both SCs experiments 
with an air–liquid interface system. As described above, the 
cells were grown on membranes and exposed to drugs under 
conditions which mimic the exposure of tissues in the respira-
tory tract. The amounts which were vaporized (5 and 20 mg) 
are contained in 1–2 typical SC containing cigarettes (Ada-
mowicz et al. 2013). As described in the results section, we 
found with both SCs clear evidence for induction of DNA 
migration in both types of indicator cells.
Taken together, the results of the present study show that 
both drugs cause DNA instability in human-derived cells at 
the chromosomal level. It is known that instability of the 
genetic material plays a key role in the etiology of human 
cancer (Ferguson et al. 2015). Furthermore, it is also 
involved in neurodegenerative disorders (Madabhushi et al. 
2014), infertility (Evgeni et al. 2015) and accelerated aging 
(Ermolaeva and Schumacher 2014). Therefore, the findings 
of our investigation indicate that adverse health effects may 
be caused in drug users as a consequence of the DNA-dam-
aging properties of the drugs, and further investigations are 
warranted to clarify this important issue.
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